Live Breaking News & Updates on Phase iii

Stay informed with the latest breaking news from Phase iii on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Phase iii and stay connected to the pulse of your community

Innovent thyroid eye therapy hits phase III goal, spurs China NDA

In a crowded thyroid eye disease (TED) space, Innovent Biologics Inc. reported positive late-stage findings for its TED therapy, IBI-311, spurring the Suzhou, China-based biopharma to file for regulatory approval in China.

Suzhou , Jiangsu , China , Innovent-biologics-inc , Innovent-biologics , Innovent-biologics-inc- , Phase-iii , Thyroid-eye-disease , Ted , Ibi-311 , Ind

Bridgebio seeks Japan approval of acoramidis for rare heart disease

Armed with strong phase III safety data in Japanese patients, Palo Alto, Calif.-based Bridgebio Pharma Inc. is planning to file for Japan approval of its investigational drug acoramidis for a rare heart disorder.

Japan , Japanese , Pharma-inc , Palo-alto , Bridgebio-pharma , Bridgebio-pharma-inc- , Bioworld , Asia-pacific , Acoramidis , Attr-cm , Cardiovascular

Ambitious eCourts Ph-3 project gets Rs 825 crore this fiscal, Rs 1500 crore for next FY

The eCourts Mission Mode Project has been described by the government as the prime mover for improving access to justice using technology. As part of phase-III, the system will be migrated to cloud technology and the cost estimated for providing 25 petabytes (according to existing requirement) of cloud storage is Rs 1,205.20 crore.

Law-ministry , Courts-mission-mode , Courts-mission-mode-project , Ecourts , Phase-iii , Digital-infrastructure , Budget-estimates , Lower-judiciary , Cloud-technology , Petabytes , Cabinet

Tiger Census: 40-day Phase Iii Tiger Census Launched In Mtr | Coimbatore News

Udhagamandalam: A 40-day tiger census of phase III for the year 2023-24 through auto-camera traps was launched in the core area of the Mudumalai Tiger.

Madhya-pradesh , India , Rampuri , Maharashtra , Mudumalai , Tamil-nadu , Udhagamandalam , Seoni , Brajesh-bharadwaj , Manoj-kumar , National-tiger-conservation-authority , Mudumalai-tiger-reserve

Explainer: Interesting details about KICC as building lined up for sale

It was designed to be a symbol of unity, progress, and global connectivity.

Nairobi , Nairobi-area , Kenya , David-mutiso , Njuguna-ndungu , Karl-henrik , Solel-boneh-factah , Nick-salat , Jomo-kenyatta , Kenyatta-international-conference-centre , Global-conference-on-health , World-bank-conference

NTHATISI MOLEFE-NYEMBE | Vaccines bring some hope in fight against malaria

The parasite causing malaria,Plasmodium spp, was discovered in 1880 by Sir Charles Louis Alphonse Laveran.

Egypt , Ghana , Durban , Kwazulu-natal , South-africa , Mali , Kenya , Italy , Nigeria , Orange-river , Free-state , Malawi

Sarepta sinks as Elevidys misses DMD endpoint in confirmatory trial

Failing to meet the primary endpoint in its confirmatory phase III Embark trial, Sarepta Therapeutics Inc.’s gene therapy, Elevidys (delandistrogene moxeparvovec), which received accelerated approval in June and was priced at $3.2 million, has one of three fates in its future, all of which are dependent on how the U.S. FDA perceives the data.

Sarepta-therapeutics-inc , Sarepta-therapeutics , Sarepta-therapeutics-inc- , Elevidys , Delandistrogene-moxeparvovec , Duchenne-muscular-dystrophy , Dmd , Embark , Phase-iii ,

Reviva's brilaroxazine hits phase III schizophrenia endpoint, propels stock upward

The pivotal phase III study of brilaroxazine from Reviva Pharmaceuticals Holdings Inc. for adults with schizophrenia hit its primary endpoint and two key secondary endpoints, following positive phase II data in 2021. The serotonin-dopamine signaling modulator, the company’s lead candidate, is a once-daily treatment.

Reviva-pharmaceuticals-holdings-inc , Reviva-pharmaceuticals-holdings , Schizophrenia , Minerva-neurosciences-inc- , Karxt , Phase-iii , Karuna-therapeutics-inc- , Brilaroxazine , Reviva-pharmaceuticals-holdings-inc- , Cerevel-therapeutics-holdings-inc- ,

Dato data lack upside for Gilead; Padcev 'must-win' does win

Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form the basis of global approval bids, as Astrazeneca plc with Daiichi Sankyo Co. Ltd. unveiled interim results from a study called Tropion-Breast01. Targeting trophoblast cell surface antigen 2, datopotamab deruxtecan (dato) hit the mark in progression-free survival for patients with hormone receptor-positive, HER2-low or negative breast cancer in the study called Tropion-Breast01.

Daiichi-sankyo-co , Astrazeneca , Daiichi-sankyo , Phase-iii , Merck-amp-co-inc- , Keytruda , Padcev , Astellas-pharma-inc- , Eisai-co-ltd- , Lenvima , Metastatic-urothelial-carcinoma

Dato data lack means upside for Gilead; Padcev 'must-win' does win

Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form the basis of global approval bids, as Astrazeneca plc with Daiichi Sankyo Co. Ltd. unveiled interim results from a study called Tropion-Breast01. Targeting trophoblast cell surface antigen 2, datopotamab deruxtecan (dato) hit the mark in progression-free survival for patients with hormone receptor-positive, HER2-low or negative breast cancer in the study called Tropion-Breast01.

Daiichi-sankyo-co , Astrazeneca , Daiichi-sankyo , Phase-iii , Merck-amp-co-inc- , Keytruda , Padcev , Astellas-pharma-inc- , Eisai-co-ltd- , Lenvima , Metastatic-urothelial-carcinoma